Quoin Pharmaceuticals Welcomes Dr. Glickman to Board for Genome Editing Growth Initiatives
- Specific Biologics appoints Dr. Richard Glickman to its Board, enhancing leadership for growth in genome editing.
- Glickman’s experience in biotech and successful acquisitions will aid Specific Biologics' development of Dualase® technology.
- The company aims to address genetic diseases, like ALS, while transitioning leadership to strengthen governance and operations.
Specific Biologics Appoints Dr. Richard Glickman to Board, Aiming at Growth in Genome Editing
Specific Biologics Inc., a precision in vivo genome editing company, enhances its leadership with the appointment of Dr. Richard Glickman to its Board of Directors. Dr. Glickman arrives with an extensive background in biotechnology, bringing over three decades of experience that includes founding prominent companies such as StressGen Biotechnologies and Aspreva Pharmaceuticals. His notable accomplishments include leading Aspreva to a successful acquisition valued at US$915 million. Glickman’s expertise in guiding biotech firms through various developmental stages is a significant asset for Specific Biologics, particularly as it seeks to advance its innovative Dualase® genome editing technology.
The Chair of the Board, Paul J. Hastings, expresses enthusiasm for Dr. Glickman’s appointment, citing his proven track record in building successful biotech enterprises and fostering innovation. Dr. Glickman, in turn, acknowledges the potential of Specific Biologics to tackle pressing genetic diseases, particularly amyotrophic lateral sclerosis (ALS), where current therapies remain inadequate. This collaboration is poised to leverage Dr. Glickman’s extensive industry experience, positioning Specific Biologics to capitalize on opportunities in the fast-evolving field of genetic medicine. His eagerness to work alongside the existing leadership team signifies a united front as the company embarks on a new growth phase.
In addition to welcoming Dr. Glickman, Specific Biologics announces the departure of Frédéric Lemaître Auger from the Board. His contributions have been pivotal in shaping the company’s strategic initiatives since its inception. This leadership transition reflects Specific Biologics’ commitment to enhancing its governance and operational capabilities as it seeks to expand its impact in the biotechnology sector. With Dr. Glickman’s expertise and the ongoing focus on innovative genome editing technologies, Specific Biologics is well-positioned to make significant strides in addressing critical genetic disorders.
In a related development, Norgine, a European specialty pharmaceutical company, enters into an exclusive licensing agreement with Vir Biotechnology to market a combination therapy for chronic hepatitis delta (CHD). This collaboration aims to address the pressing unmet medical needs associated with CHD, offering hope for patients through innovative treatment options. Both companies are committed to clinical development, sharing costs and responsibilities, which showcases their dedication to improving healthcare outcomes in this challenging area.
Norgine's CEO, Janneke van der Kamp, underlines the strategic significance of this partnership in enhancing their portfolio, particularly in hepatology. This deal not only strengthens Norgine’s position in the specialty pharmaceuticals market but also highlights the broader industry trend towards collaboration in developing effective therapies for complex health issues.